4 Sep 2019: Published in Clinical Cancer Research (https://clincancerres.aacrjournals.org/content/early/2019/09/04/1078-0432.CCR-19-0421). This paper by our academic collaborators at Baylor College of Medicine, summarizes…
Allogeneic “off the shelf” chimeric antigen receptor-natural killer T cell (CAR-NKT) therapy platform could overcome significant challenges of current autologous CAR-T…
Early data show highly innovative chimeric antigen receptor-natural killer T cell (CAR-NKT) therapy homing to and shrinking solid tumors in neuroblastoma…
Collaboration with Baylor College of Medicine and Texas Children’s Hospital includes ground-breaking GINAKIT2 Phase 1 trial GINAKIT2 is evaluating highly innovative…
Ground-breaking Phase 1 trial, GINAKIT2, part of Cell Medica’s collaboration with Baylor College of Medicine and Texas Children’s Hospital Study is…
Cell Medica Announces Publication of ASPIRE Clinical Trial Results All Patients Cleared Adenovirus Infection Following Cytovir ADV™ Treatment The results of…